Quest Diagnostics Incorporated is buying cancer-detection company Haystack Oncology for $300m in cash with plans to launch their liquid biopsy test in 2024, the companies announced on 27 April.
Baltimore-based Haystack Oncolgy, whose liquid biopsy technology is based on research from renowned Johns Hopkins University oncologists Bert Vogelstein, Ken Kinzler and Nickolas Papadopoulos, has developed a test to detect...